222 related articles for article (PubMed ID: 36968132)
1. Growth Restriction in Preeclampsia: Lessons from Animal Models.
Mallette JH; Crudup BF; Alexander BT
Curr Opin Physiol; 2023 Apr; 32():. PubMed ID: 36968132
[TBL] [Abstract][Full Text] [Related]
2. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
Groom KM; David AL
Am J Obstet Gynecol; 2018 Feb; 218(2S):S829-S840. PubMed ID: 29229321
[TBL] [Abstract][Full Text] [Related]
3. Animal models of preeclampsia: investigating pathophysiology and therapeutic targets.
Bakrania BA; George EM; Granger JP
Am J Obstet Gynecol; 2022 Feb; 226(2S):S973-S987. PubMed ID: 33722383
[TBL] [Abstract][Full Text] [Related]
4. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.
Rana S; Burke SD; Karumanchi SA
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1019-S1034. PubMed ID: 33096092
[TBL] [Abstract][Full Text] [Related]
5. Expert review: preeclampsia Type I and Type II.
Yagel S; Cohen SM; Admati I; Skarbianskis N; Solt I; Zeisel A; Beharier O; Goldman-Wohl D
Am J Obstet Gynecol MFM; 2023 Dec; 5(12):101203. PubMed ID: 37871693
[TBL] [Abstract][Full Text] [Related]
6. The role of immune cells and mediators in preeclampsia.
Deer E; Herrock O; Campbell N; Cornelius D; Fitzgerald S; Amaral LM; LaMarca B
Nat Rev Nephrol; 2023 Apr; 19(4):257-270. PubMed ID: 36635411
[TBL] [Abstract][Full Text] [Related]
7. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction.
Arenas GA; Tang NY; Mueller A; Lopes Perdigao J; Kaur H; Abramowicz JS; Mussatt K; Yeo KJ; Rana S
Am J Obstet Gynecol MFM; 2021 Jul; 3(4):100394. PubMed ID: 33991706
[TBL] [Abstract][Full Text] [Related]
8. Uterine and fetal placental Doppler indices are associated with maternal cardiovascular function.
Tay J; Masini G; McEniery CM; Giussani DA; Shaw CJ; Wilkinson IB; Bennett PR; Lees CC
Am J Obstet Gynecol; 2019 Jan; 220(1):96.e1-96.e8. PubMed ID: 30243605
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines: An approach to treat placental insufficiency and the current challenges.
van Kammen CM; van Woudenberg SJ; Schiffelers R; Terstappen F; Lely AT
J Control Release; 2023 Aug; 360():57-68. PubMed ID: 37330012
[TBL] [Abstract][Full Text] [Related]
10. Chronic hypertension and superimposed preeclampsia: screening and diagnosis.
Kametas NA; Nzelu D; Nicolaides KH
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1182-S1195. PubMed ID: 35177217
[TBL] [Abstract][Full Text] [Related]
11. Placental transcriptional and histologic subtypes of normotensive fetal growth restriction are comparable to preeclampsia.
Gibbs I; Leavey K; Benton SJ; Grynspan D; Bainbridge SA; Cox BJ
Am J Obstet Gynecol; 2019 Jan; 220(1):110.e1-110.e21. PubMed ID: 30312585
[TBL] [Abstract][Full Text] [Related]
12. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia.
Burton GJ; Yung HW; Cindrova-Davies T; Charnock-Jones DS
Placenta; 2009 Mar; 30 Suppl A(Suppl):S43-8. PubMed ID: 19081132
[TBL] [Abstract][Full Text] [Related]
13. The Role of Different Lymphoid Cell Populations in Preeclampsia Pathophysiology.
Campbell NE; Deer EM; Herrock OT; LaMarca BB
Kidney360; 2022 Oct; 3(10):1785-1794. PubMed ID: 36514732
[TBL] [Abstract][Full Text] [Related]
14. Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia.
Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2022 Aug; 227(2):294.e1-294.e11. PubMed ID: 35276067
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Sequels During and After Preeclampsia.
Paauw ND; Lely AT
Adv Exp Med Biol; 2018; 1065():455-470. PubMed ID: 30051401
[TBL] [Abstract][Full Text] [Related]
16. Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction.
de Alwis N; Beard S; Binder NK; Pritchard N; Kaitu'u-Lino TJ; Walker SP; Stock O; Groom K; Petersen S; Henry A; Said JM; Seeho S; Kane SC; Tong S; Hui L; Hannan NJ
Antioxidants (Basel); 2022 Aug; 11(9):. PubMed ID: 36139751
[TBL] [Abstract][Full Text] [Related]
17. Comparative Characteristics of Sialoglycans Expression Disorders in the Placental Barrier Structures in Preeclampsia and Fetal Growth Restriction.
Ziganshina MM; Kulikova GV; Shchegolev AI; Shmakov RG; Kan NE; Sukhikh GT
Bull Exp Biol Med; 2022 Jun; 173(2):270-275. PubMed ID: 35739329
[TBL] [Abstract][Full Text] [Related]
18. Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction.
Fosheim IK; Jacobsen DP; Sugulle M; Alnaes-Katjavivi P; Fjeldstad HES; Ueland T; Lekva T; Staff AC
Am J Obstet Gynecol MFM; 2023 Jan; 5(1):100794. PubMed ID: 36334725
[TBL] [Abstract][Full Text] [Related]
19. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.
Yagel S; Cohen SM; Goldman-Wohl D
Am J Obstet Gynecol; 2022 Feb; 226(2S):S963-S972. PubMed ID: 33712272
[TBL] [Abstract][Full Text] [Related]
20. Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes.
Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2021 May; 224(5):518.e1-518.e11. PubMed ID: 33166504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
